Dr. Jason Field’s separates facts from fiction in a constructive www.healthydebate.ca article (https://healthydebate.ca/opinions/failed-drug-pricing-policy/). When other countries were working collaboratively with the life sciences sector as soon as #COVID hit, Health Canada was imposing drastic and uncertain price controls. Myths are separated from facts on key issues, including How much Canadians actually spend…
Elizabeth Voss
Canada’s life sciences sector has been at the forefront of our country’s response to the COVID-19 pandemic. Our sector also has significant potential to drive Canada’s economic recovery and build up our resilience to future health challenges. In this context, life sciences sector stakeholders remain deeply concerned about the federal…
In these unprecedented times, access to new medicines and vaccines has never been more important. However, new federal drug pricing regulations changing the Patented Medicine Prices Review Board (PMPRB) are hurting Canadians’ access to new life-saving medicines and vaccines. According to a recent Research Etc. survey of 43 pharmaceutical leaders:…
TORONTO–(BUSINESS WIRE)–LSO today announced the recipients of its 2021 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontario’s life sciences sector. The awards will be presented during LSO’s Celebration of Success Awards in February 2021. The 2021 awardees are as follows: Lifetime Achievement Award: Michael Julius Community Service…
Subject: HESA study on the reforms of the Patented Medicine Prices Review Board (PMPRB) Dear Honourable Members,Life Sciences Ontario (LSO) is a not-for-profit organization that represents and promotes Ontario’s vibrant and diverse life sciences sector. Members of LSO include life sciences companies, entrepreneurs, members of academia, and service providers from…
Toronto, Ontario – LSO remains concerned by today’s release of the final PMPRB guidelines implementing the federal government’s patented medicine price controls. The final guidelines create a highly risky and uncertain pathway for commercializing new medicines and vaccines in Canada. LSO President and CEO Jason Field wants to ask the…
Life Sciences Ontario remains deeply concerned about the federal government’s patented medicine price controls and their potential to undermine the life sciences sector’s efforts to support the health and well-being of Canadians and the economy, particularly during the unprecedented COVID-19 pandemic. There is a growing body of evidence showing that…
Toronto, Ontario – In a time when the world is facing unparalleled uncertainty surrounding COVID-19, it has become increasingly apparent how integral the life sciences sector is to our society. The life sciences sector is at the forefront globally in combating the spread and developing vaccines and treatments to slow the…
Canada has long been considered a top global jurisdiction for new medicine launches. However, recent federal drug price controls have cast doubts on whether Canada can maintain this status. To help inform and contribute to this discussion, Life Sciences Ontario commissioned IQVIA – a global leader in health data and…
Life Sciences Ontario applauds the federal government’s recent decision to delay the implementation of the Patented Medicines Regulations to January 1, 2021 as part of the response to the COVID-19 crisis. This measure will help the Canadian life sciences sector remain unwaveringly focused on developing vaccines, treatments, and other tools to fight…